hydroxychloroquine has been researched along with Muscle Weakness in 8 studies
Hydroxychloroquine: A chemotherapeutic agent that acts against erythrocytic forms of malarial parasites. Hydroxychloroquine appears to concentrate in food vacuoles of affected protozoa. It inhibits plasmodial heme polymerase. (From Gilman et al., Goodman and Gilman's The Pharmacological Basis of Therapeutics, 9th ed, p970)
hydroxychloroquine : An aminoquinoline that is chloroquine in which one of the N-ethyl groups is hydroxylated at position 2. An antimalarial with properties similar to chloroquine that acts against erythrocytic forms of malarial parasites, it is mainly used as the sulfate salt for the treatment of lupus erythematosus, rheumatoid arthritis, and light-sensitive skin eruptions.
Muscle Weakness: A vague complaint of debility, fatigue, or exhaustion attributable to weakness of various muscles. The weakness can be characterized as subacute or chronic, often progressive, and is a manifestation of many muscle and neuromuscular diseases. (From Wyngaarden et al., Cecil Textbook of Medicine, 19th ed, p2251)
| Excerpt | Relevance | Reference |
|---|---|---|
| "Hydroxychloroquine is being used for COVID-19 symptoms and in clinical trials, but can cause a toxic myopathy that leads to muscle weakness." | 3.96 | Challenges in diagnosing hydroxychloroquine myopathy during the COVID-19 pandemic. ( Chan, RC; Pamphlett, R; Wang, MX, 2020) |
| "The aim of this systematic review was to perform qualitative and quantitative analysis on the toxic effects of chloroquine (CQ) and hydroxychloroquine (HCQ) on skeletal muscles." | 2.72 | The toxic effects of chloroquine and hydroxychloroquine on skeletal muscle: a systematic review and meta-analysis. ( Biguetti, CC; Brotto, M; Fiedler, MW; Junior, JFS; Marrelli, MT, 2021) |
| "A control group of 16 patients with idiopathic inflammatory myositis (IIM) on HCQ at time of biopsy but without evidence of CB was identified." | 1.46 | Curvilinear bodies are associated with adverse effects on muscle function but not with hydroxychloroquine dosing. ( Blumbergs, P; Khoo, T; Koszyca, B; Lester, S; Limaye, V; Otto, S; Smith, C, 2017) |
| "However, DM without muscle weakness is a clinical entity with respect to favorable long-term prognosis." | 1.29 | Dermatomyositis without muscle weakness. Long-term follow-up of 12 patients without systemic corticosteroids. ( Amaudric, F; Cosnes, A; Gherardi, R; Revuz, J; Roujeau, JC; Verroust, J; Wechsler, J, 1995) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (12.50) | 18.2507 |
| 2000's | 1 (12.50) | 29.6817 |
| 2010's | 4 (50.00) | 24.3611 |
| 2020's | 2 (25.00) | 2.80 |
| Authors | Studies |
|---|---|
| Pamphlett, R | 1 |
| Wang, MX | 1 |
| Chan, RC | 1 |
| Biguetti, CC | 1 |
| Junior, JFS | 1 |
| Fiedler, MW | 1 |
| Marrelli, MT | 1 |
| Brotto, M | 1 |
| Koroscil, MT | 1 |
| Rohan, CA | 1 |
| Morris, MJ | 1 |
| Scott, JN | 1 |
| Tidwell, WJ | 1 |
| Callen, JP | 1 |
| Khoo, T | 1 |
| Otto, S | 1 |
| Smith, C | 1 |
| Koszyca, B | 1 |
| Lester, S | 1 |
| Blumbergs, P | 1 |
| Limaye, V | 1 |
| Stevens, MA | 1 |
| Yeaney, GA | 1 |
| Lacomis, D | 1 |
| Haro, R | 1 |
| Revelles, JM | 1 |
| Fariña, Mdel C | 1 |
| Martín, L | 1 |
| Requena, L | 1 |
| Cosnes, A | 1 |
| Amaudric, F | 1 |
| Gherardi, R | 1 |
| Verroust, J | 1 |
| Wechsler, J | 1 |
| Revuz, J | 1 |
| Roujeau, JC | 1 |
2 reviews available for hydroxychloroquine and Muscle Weakness
| Article | Year |
|---|---|
The toxic effects of chloroquine and hydroxychloroquine on skeletal muscle: a systematic review and meta-analysis.
Topics: Adult; Aged; Creatine Kinase; Fructose-Bisphosphate Aldolase; Humans; Hydroxychloroquine; L-Lactate | 2021 |
Wong's dermatomyositis: a new case and review of the literature.
Topics: Antirheumatic Agents; Dermatomyositis; Female; Humans; Hydroxychloroquine; Middle Aged; Muscle Weakn | 2013 |
6 other studies available for hydroxychloroquine and Muscle Weakness
| Article | Year |
|---|---|
Challenges in diagnosing hydroxychloroquine myopathy during the COVID-19 pandemic.
Topics: Adult; Aged; Aged, 80 and over; Antirheumatic Agents; COVID-19; Diagnosis, Differential; Humans; Hyd | 2020 |
Wong-Type Dermatomyositis Complicated by Interstitial Lung Disease.
Topics: Adult; Anti-Inflammatory Agents; Antirheumatic Agents; Biopsy; Dermatomyositis; Diagnosis, Different | 2018 |
Koebner Phenomenon in Juvenile Dermatomyositis.
Topics: Adolescent; Anti-Inflammatory Agents; Antirheumatic Agents; Biopsy; Creatine Kinase; Dermatologic Ag | 2018 |
Curvilinear bodies are associated with adverse effects on muscle function but not with hydroxychloroquine dosing.
Topics: Antirheumatic Agents; Databases, Factual; Humans; Hydroxychloroquine; Muscle Weakness; Muscle, Skele | 2017 |
42-year-old man with discoid lupus and progressive weakness.
Topics: Adult; Antirheumatic Agents; Humans; Hydroxychloroquine; Lupus Erythematosus, Systemic; Male; Micros | 2009 |
Dermatomyositis without muscle weakness. Long-term follow-up of 12 patients without systemic corticosteroids.
Topics: Adolescent; Adrenal Cortex Hormones; Adult; Aged; Antirheumatic Agents; Case-Control Studies; Child; | 1995 |